Researchers discover that people share the same cancer-causing mutations as felines ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

The presentation of chronic feline gingivostomatitis is often dramatic. Clinical signs include severe refractory gingivostomatitis, halitosis, ptyalism, and unkempt hair coats due to a lack of ...

Johnson & Johnson (NYSE:JNJ) received FDA Breakthrough Therapy Designation for subcutaneous amivantamab as a monotherapy in recurrent or metastatic head and neck squamous cell carcinoma. In a separate ...

USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion in 2026 to an estimated $748.17 billion by 2035[1].

International team uncovers gene mutations that cause rare and aggressive cancer in both cats and humans. Their findings could provide a path to treatments for both species.

Q4 2025 Earnings Call February 26, 2026 4:30 PM ESTCompany ParticipantsMike Brophy - Chief Financial OfficerSteve Chapman - CEO ...

SIOUX FALLS, SD - January 23, 2026 - PRESSADVANTAGE - Vance Thompson Vision is drawing attention to its advanced ...

These new findings are prompting a strategic review of the administration schedule. Bicara is currently conducting its pivotal Phase 3 trial, known as FORTIFI-HN01, using a weekly 1500 mg dose.

Young women with a history of cervical lesions are at 20% higher risk of developing cardiovascular disease and more likely to ...

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s ...